Arcellx (ACLX) Cash from Operations (2021 - 2025)
Arcellx's quarterly Cash from Operations came in at 58175000.0 in Q4 2025, down 26.38% year-on-year from 79025977.57 in Q4 2024, and down 18.23% quarter-over-quarter from 49207000.0 in Q3 2025.
Arcellx has reported Cash from Operations for 5 years, with the latest figure at 58175000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations fell 26.38% year-over-year to 58175000.0; the trailing twelve-month figure through Dec 2025 stood at 210258000.0 (down 151.91% YoY), and the FY2025 full-year result was 210258000.0, down 151.91% from the prior year.
- Cash from Operations for Q4 2025 stood at 58175000.0, down from 49207000.0 in the prior quarter.
- The five-year high for Cash from Operations was 182042000.0 in Q1 2023, with the low at 63145000.0 in Q1 2025.
- Average Cash from Operations over 5 years is 11984650.0, with a median of 22581500.0 recorded in 2022.
- Year-over-year, Cash from Operations soared 658.65% in 2023 and plunged 260.18% in 2025.
- Tracing ACLX's Cash from Operations over 5 years: stood at 21546000.0 in 2021, then fell by 27.73% to 27520000.0 in 2022, then soared by 311.66% to 58248000.0 in 2023, then tumbled by 179.02% to 46030000.0 in 2024, then retreated by 26.38% to 58175000.0 in 2025.
- The last three Cash from Operations figures came in at 58175000.0 (Q4 2025), 49207000.0 (Q3 2025), and 39731000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | -58.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -58.18 Mn |
| Dec 31, 2025 | -58.18 Mn |
| Sep 30, 2025 | -49.21 Mn |
| Sep 30, 2025 | -49.21 Mn |
| Jun 30, 2025 | -39.73 Mn |
| Jun 30, 2025 | -39.73 Mn |
| Mar 31, 2025 | -63.15 Mn |
| Mar 31, 2025 | -63.15 Mn |
| Dec 31, 2024 | -46.03 Mn |
| Dec 31, 2024 | -46.03 Mn |
| Sep 30, 2024 | 30.72 Mn |
| Sep 30, 2024 | 30.72 Mn |
| Jun 30, 2024 | -36.25 Mn |
| Jun 30, 2024 | -36.25 Mn |
| Mar 31, 2024 | -31.91 Mn |
| Mar 31, 2024 | -31.91 Mn |
| Dec 31, 2023 | 58.25 Mn |
| Dec 31, 2023 | 58.25 Mn |
| Sep 30, 2023 | -10.10 Mn |
| Sep 30, 2023 | -10.10 Mn |
| Jun 30, 2023 | -22.62 Mn |
| Jun 30, 2023 | -22.62 Mn |
| Mar 31, 2023 | 182.04 Mn |
| Mar 31, 2023 | 182.04 Mn |
| Dec 31, 2022 | -27.52 Mn |
| Dec 31, 2022 | -27.52 Mn |
| Sep 30, 2022 | -16.65 Mn |
| Sep 30, 2022 | -16.65 Mn |
| Jun 30, 2022 | -22.55 Mn |
| Jun 30, 2022 | -22.55 Mn |
| Mar 31, 2022 | -32.59 Mn |
| Mar 31, 2022 | -32.59 Mn |
| Dec 31, 2021 | -21.55 Mn |
| Dec 31, 2021 | -21.55 Mn |
| Sep 30, 2021 | -12.22 Mn |
| Sep 30, 2021 | -12.22 Mn |
| Jun 30, 2021 | -10.96 Mn |
| Jun 30, 2021 | -10.96 Mn |
| Mar 31, 2021 | -9.51 Mn |
| Mar 31, 2021 | -9.51 Mn |